Ipsen: Oddo remains a buyer ahead of ISPRM Congress
(CercleFinance.com) - The group will present new clinical data at the next International Society of Physical and Rehabilitation Medicine (ISPRM) congress.
Before this presentation, Oddo confirms its “buy” rating on the stock, with a target price of 133 euros.
At current levels, we believe that the share is beginning to be fairly valued, although its momentum and newsflow remain upbeat, and Ipsen has significant funds to make acquisitions.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Before this presentation, Oddo confirms its “buy” rating on the stock, with a target price of 133 euros.
At current levels, we believe that the share is beginning to be fairly valued, although its momentum and newsflow remain upbeat, and Ipsen has significant funds to make acquisitions.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.